Detalhe da pesquisa
1.
Splenic iron decreases without change in volume or liver parameters during luspatercept therapy.
Blood
; 142(22): 1932-1934, 2023 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37704579
2.
Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease.
Rheumatology (Oxford)
; 63(3): 639-647, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37294870
3.
Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort.
Rheumatology (Oxford)
; 63(2): 472-481, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37228011
4.
A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's.
Rheumatology (Oxford)
; 2024 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38291895
5.
Native myocardial T1 and right ventricular size by CMR predict outcome in systemic sclerosis-associated pulmonary hypertension.
Rheumatology (Oxford)
; 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38759116
6.
Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis.
Rheumatology (Oxford)
; 2024 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38460548
7.
Decreased erythrocyte aggregation in Glenn and Fontan: univentricular circulation as a rheologic disease model.
Pediatr Res
; 95(5): 1335-1345, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38177250
8.
Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxoedema and scleroedema.
J Eur Acad Dermatol Venereol
; 2024 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38456518
9.
Enrichment strategies for clinical trials targeting skin fibrosis and interstitial lung disease in systemic sclerosis.
Curr Opin Rheumatol
; 35(6): 349-355, 2023 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37729053
10.
Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups.
Ann Rheum Dis
; 82(12): 1568-1579, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37580109
11.
Clinical and pathogenic significance of S100A4 overexpression in systemic sclerosis.
Ann Rheum Dis
; 82(9): 1205-1217, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414521
12.
Macrophages as determinants and regulators of fibrosis in systemic sclerosis.
Rheumatology (Oxford)
; 62(2): 535-545, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35861385
13.
'I turned in my man card': a qualitative study of the experiences, coping styles and support needs of men with systemic sclerosis.
Rheumatology (Oxford)
; 62(6): 2160-2167, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36205545
14.
Construct validity and reliability of the assessment of systemic sclerosis-associated raynaud's phenomenon (ASRAP) questionnaire.
Rheumatology (Oxford)
; 2023 Jul 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37481713
15.
Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial.
Rheumatology (Oxford)
; 62(5): 1870-1876, 2023 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36111858
16.
A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS).
Rheumatology (Oxford)
; 62(9): 3133-3138, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36637209
17.
Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review.
Rheumatology (Oxford)
; 62(12): 3785-3800, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37335850
18.
Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease.
Rheumatology (Oxford)
; 62(5): 1877-1886, 2023 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36173318
19.
Skin biopsy analysis of concurrent keloidal morphoea and systemic sclerosis confirms overlapping pathogenic pathways.
Clin Exp Rheumatol
; 41(8): 1644-1651, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37223904
20.
Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.
Am J Respir Crit Care Med
; 205(6): 674-684, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34851799